Tag: 300

Strong operating results following a strategic transition to a pure-play industrial REIT

Des résultats d'exploitation robustes à la suite d'une transition stratégique vers un FPI purement industriel

Posts Positive Organic Growth and Adjusted EBITDA^‎1 of 23.5% of Revenue

Achieves Positive Net Income in the Second Quarter and Positive Adjusted EBITDA¹ for the Second Quarter and Six Months Ended June 30, 2025 

ARLINGTON, Va., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its results for the three and nine months ended June 30, 2025.

DARIEN, Conn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Carronade Capital Management, LP on behalf of its managed entities (“Carronade Capital”, “our” or “we”), which beneficially own approximately 3.2 million shares of Common Stock of Cannae Holdings, Inc. (NYSE: CNNE) (“Cannae” or the “Company”) and is one of the Company’s top shareholders, today posed important questions that it believes shareholders would like to see answered by Cannae’s executive team during its second quarter 2025 earnings call scheduled for 5:00 pm ET on August 11, 2025.

DALLAS, Aug. 11, 2025 (GLOBE NEWSWIRE) -- HF Sinclair Corporation (NYSE and NYSE Texas: DINO) (the “Corporation”) today announced that it has commenced a cash tender offer (the “Tender Offer”) to purchase any and all of the outstanding notes listed in the table below (collectively, the “Notes” and each a “Series” of Notes).

Katy, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- CW Petroleum Corp (OTCQB: CWPE) (the “Company” or “CWPE”), a leading provider of Specialty Renewable and Hydrocarbon Motor Fuels, today announces to its investors and future investors that it has reduced its Authorized Shares of Common Stock from 300,000,000 to 150,000,000, a 50% reduction.

STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on CEO interviews and corporate events.